Last Updated: November 16, 2026

Details for Patent: 11,103,513

« Back to Dashboard


Which drugs does patent 11,103,513 protect, and when does it expire?

Patent 11,103,513 protects BIJUVA and is included in one NDA.

This patent has nine patent family members in nine countries.

Summary for Patent: 11,103,513
Title:Natural combination hormone replacement formulations and therapies
Abstract:Pharmaceutical compositions for co-administering estradiol and progesterone to a human subject in need thereof are provided. In some embodiments, the pharmaceutical composition comprises solubilized estradiol, suspended progesterone, and a solubilizing agent comprising a medium chain (C6-C12) oil.
Inventor(s):Brian A. Bernick, Peter H. R. Persicaner, Julia M. Amadio
Assignee: TherapeuticsMD Inc
Application Number:US16/885,088
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 11,103,513
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

United States Patent 11,103,513: Scope, Claims, Expiration, and Bijuva Patent Landscape

US Patent No. 11,103,513 protects methods of treating menopausal vasomotor symptoms with an oral, food-administered capsule containing 1 mg of 17β-estradiol and 100 mg of progesterone. The patent is directed to the Bijuva formulation and combines composition limitations with pharmacokinetic performance requirements.

The strongest infringement risk applies to products that reproduce the capsule’s medium-chain lipid formulation, largely solubilized estradiol, partly solubilized and micronized progesterone, and the claimed exposure ranges. The patent does not broadly cover every estradiol/progesterone product. Its method claims require a particular patient population, administration with food, dosage form, formulation architecture, and pharmacokinetic result.

What drug and product does US Patent 11,103,513 protect?

US 11,103,513 is associated with the oral estradiol/progesterone product Bijuva, approved by the FDA under NDA 210366. Bijuva contains:

Component Amount per capsule
17β-estradiol 1 mg
Progesterone 100 mg
Dosage form Oral softgel capsule
Administration With food
Indication Moderate-to-severe vasomotor symptoms due to menopause in women with a uterus

The formulation uses a lipid-based fill material. Estradiol is substantially solubilized. Progesterone is divided between a solubilized portion and a micronized, uniformly dispersed portion.

The FDA approved Bijuva on October 10, 2018, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with a uterus. The progesterone component provides endometrial protection for women receiving systemic estrogen therapy.[1]

What are the core claim elements of US 11,103,513?

The patent contains 30 claims. Claims 1, 9, 12, and 17 are the principal independent claims. The remaining claims narrow those methods through additional patient, formulation, particle-size, ratio, and pharmacokinetic limitations.

Claim 1: narrow closed-composition method

Claim 1 requires all of the following:

  1. A female human patient with vasomotor symptoms associated with estrogen deficiency.
  2. Oral administration with food.
  3. A capsule.
  4. A fill material consisting of:
    • About 196 mg of mono- and diglycerides of caprylic and capric acid.
    • About 3 mg of lauroyl macrogol-32 glycerides, lauroyl polyoxyl-32 glycerides, or lauroyl polyoxylglycerides.
    • About 1 mg of 17β-estradiol.
    • About 100 mg of progesterone.
  5. At least about 80% of the estradiol solubilized in the solubilizing agent.
  6. A first progesterone portion solubilized and a second portion micronized.
  7. Uniform dispersion of the micronized progesterone.
  8. The entire estradiol and progesterone quantities present in the solubilizing agent.
  9. At least one specified estradiol, estrone, or progesterone pharmacokinetic parameter.

The use of “consisting of” in the fill-material definition makes claim 1 materially narrower than the claims using “comprising.” An accused product containing an additional fill-material component could raise a literal infringement issue under claim 1, although the effect would depend on claim construction and the role of the additional ingredient.

Claim 9: broader fixed-formulation method

Claim 9 covers substantially the same formulation but uses “comprising” for the fill material and solubilizing agent. That language generally permits additional components, subject to the remaining limitations.

Claim 9 also requires that no more than about 15% by weight of the progesterone is solubilized in the solubilizing agent. This creates a formulation constraint that is narrower than the broader independent formulation concept in claim 1.

Claim 12: functional lipid-system method

Claim 12 moves away from named excipients and covers a functional formulation defined by:

  • A medium-chain oil with at least about 80% of fatty acid chains in the C6-C12 range.
  • The medium-chain oil comprising about 60% to about 85% of the fill material by weight.
  • A nonionic surfactant comprising about 0.1% to about 10.0% of the fill material.
  • About 1 mg of estradiol.
  • About 100 mg of progesterone.
  • At least about 80% of estradiol solubilized.
  • A micronized progesterone portion uniformly dispersed in the solubilizing agent.
  • The claimed pharmacokinetic outcome.

Claim 12 is potentially important for design-around analysis because it is not limited to the specific 196 mg and 3 mg quantities recited in claims 1 and 9.

Claim 17: broad composition-percentage method

Claim 17 defines the formulation using weight percentages:

  • Estradiol: about 0.15% to about 0.4% of the fill material.
  • Progesterone: about 30% to about 35% of the fill material.
  • Up to about 20% of progesterone solubilized.
  • The remaining progesterone micronized and uniformly dispersed.
  • At least about 80% of estradiol solubilized.
  • A surfactant may be added in dependent claims.

This claim is commercially relevant because the formulation ranges can capture products with different absolute excipient quantities, provided the resulting capsule satisfies the drug-content, structural, administration, and pharmacokinetic limitations.

What pharmacokinetic parameters are required by the patent?

The claims use pharmacokinetic ranges as claim limitations. At least one listed parameter is required in independent claims 1, 9, 12, and 17.

Analyte Parameter Claimed range
17β-estradiol AUC(0-t) 561.4933 to 877.3333 pg·hr/mL
17β-estradiol Cmax 25.9161 to 40.4939 pg/mL
Estrone AUC(0-t) 3,638.4363 to 5,685.0567 pg·hr/mL
Estrone Cmax 170.6197 to 266.5933 pg/mL
Progesterone AUC(0-t) 48.0348 to 75.0543 ng·hr/mL
Progesterone Cmax 35.6889 to 55.7639 ng/mL
Progesterone Tmax 2.4 to 3.8 hours
Estrone Tmax 4.4 to 6.9 hours

The ranges appear to be derived from clinical pharmacokinetic data and are expressed as population or study-performance boundaries. In an infringement dispute, the testing protocol would be central. Relevant variables could include fed-state meal composition, sampling schedule, assay methodology, patient population, formulation batch, and statistical treatment of the measured values.

A product with the same nominal drug amounts may avoid infringement if it does not produce the claimed exposure range. Conversely, a product with different excipient quantities could present risk under claims 12 or 17 if it produces the claimed pharmacokinetic profile and satisfies the structural limitations.

How do the dependent claims narrow patent protection?

The dependent claims create several narrower infringement pathways.

Claims Limitation
2, 10, 13, 18 Patient has a uterus
3, 11, 14 Progesterone or estrone Tmax range
4 At least three listed pharmacokinetic parameters
5 Five specified pharmacokinetic parameters
6 At least 15% progesterone solubilized and at least 50% micronized
7, 16, 30 Up to about 15% progesterone solubilized
8, 25 Micronized progesterone X50 below 15 microns, X90 below 25 microns, or both
15 Medium-chain oil to surfactant ratio of about 60:1 to 70:1
19 Surfactant at about 0.1% to 5% of fill material
20 Ionic, nonionic, or combined surfactant
21 Medium-chain fatty acid ester of polyethylene glycol
22 PEG glyceride composed of mono-, di-, and triglycerides and PEG mono- and diesters
23 PEG-32 glyceryl laurate EP
24, 29 Solubilizing-agent-to-nonionic-surfactant ratio of about 65:1
26, 27 Medium-chain oil with at least about 75% medium-chain fatty acids
28 Solubilizing-agent-to-surfactant ratio of about 60:1 to 70:1

The particle-size limitations in claims 8 and 25 are particularly relevant to manufacturing. A generic manufacturer would need to characterize micronized progesterone by the same or a sufficiently comparable particle-size methodology. “X50” and “X90” can vary depending on laser-diffraction settings, dispersion conditions, and calculation method.

When does US Patent 11,103,513 expire?

The patent is part of a family directed to the estradiol/progesterone formulation and methods of use. Its ordinary patent-term endpoint is expected to fall in the same general period as the family’s November 2, 2032 expiration date, subject to any applicable patent-term adjustment, terminal disclaimer, or regulatory patent-term extension.

Event Date
Earliest reported priority date for the family November 4, 2011
U.S. nonprovisional filing associated with the family November 2, 2012
Patent issued August 31, 2021
Expected family expiration November 2, 2032
FDA approval of Bijuva October 10, 2018

A patent expiration date should be confirmed against the current USPTO patent record and Orange Book listing before relying on it in a launch or transaction decision. Patent-term adjustment and terminal-disclaimer information control the operative date.[2]

What is the Orange Book status of Bijuva?

Bijuva is an FDA-approved prescription drug listed in the Orange Book under NDA 210366. The relevant regulatory protections are different from the patent protections:

  • FDA approval does not itself establish freedom to operate.
  • Orange Book-listed patents can support a Paragraph IV notice and patent litigation.
  • A 30-month stay may arise if the NDA holder or patent owner files suit within the statutory period after receiving a Paragraph IV notice.
  • Bijuva is a small-molecule combination product, not a biologic, so biosimilar provisions under the Biologics Price Competition and Innovation Act do not apply.
  • The relevant abbreviated pathway is an ANDA, subject to sameness and bioequivalence requirements.

Bijuva received three-year new clinical investigation exclusivity associated with the 2018 approval. That regulatory exclusivity does not extend through the patent term and would not, by itself, block an ANDA after the exclusivity period ended.[1,3]

What Paragraph IV challenges and generic entry risks affect Bijuva?

A generic applicant seeking approval before listed patent expiration would typically evaluate one or more certifications under the Hatch-Waxman framework:

Certification Practical meaning
Paragraph I No patent information is listed
Paragraph II Listed patent has expired
Paragraph III Applicant will wait until patent expiration
Paragraph IV Listed patent is invalid, unenforceable, or not infringed

The primary generic risk does not arise from the 1 mg/100 mg drug combination alone. It arises from reproducing the protected delivery system and achieving the claimed pharmacokinetic ranges.

A generic applicant could pursue several strategies:

  1. Challenge the patent directly through a Paragraph IV certification.
  2. Develop a formulation that uses a different lipid system.
  3. Alter the solubilized-to-micronized progesterone ratio.
  4. Target a different particle-size distribution.
  5. Use a different surfactant or a different oil-to-surfactant ratio.
  6. Seek a formulation that falls outside the claimed pharmacokinetic ranges.
  7. Delay commercial launch until relevant patent expiration.

The product-specific PK limitations may complicate both sides’ positions. They can narrow the literal scope of the claims, but they can also make noninfringement difficult to establish if the proposed ANDA product is required to demonstrate bioequivalence to Bijuva.

Which companies are challenging the Bijuva patent estate?

Publicly available information must be separated into confirmed litigation and ordinary generic-development activity. An ANDA filing, tentative approval, or commercial generic listing does not by itself establish a filed Paragraph IV case.

For US 11,103,513 specifically, the patent number, assignee, and claim text alone do not establish that a particular company has filed a Paragraph IV certification or that a federal patent case is pending. A litigation search must be performed at the patent, NDA, and district-court docket levels. The relevant parties may include the NDA holder, current patent owner, licensees, ANDA applicants, and authorized generic partners.

The absence of a confirmed case tied to this patent in the supplied record should not be treated as proof that no Paragraph IV notice or settlement exists.

What licensing and ownership issues affect the patent?

The commercial rights associated with Bijuva have changed over time. TherapeuticsMD developed and commercialized the product before its women’s-health assets were transferred to or acquired by Mayne Pharma. The patent landscape should therefore distinguish:

  • Original inventor and applicant.
  • Patent assignee at issuance.
  • Current patent owner.
  • NDA holder.
  • Commercial licensee.
  • Authorized-generic or distribution partner.

Assignment records at the USPTO and FDA’s current NDA records are more reliable than historical press releases for determining who can enforce the patent. A license agreement may also allocate enforcement rights, royalties, settlement authority, and responsibility for Orange Book maintenance.

How strong is the patent estate for Bijuva?

The estate has moderate structural strength but is narrower than a basic composition patent.

Strengths

  • It covers the marketed 1 mg estradiol/100 mg progesterone formulation architecture.
  • It includes formulation claims using named excipients and broader functional lipid definitions.
  • It claims both product structure and resulting pharmacokinetics.
  • It covers micronized progesterone particle-size characteristics.
  • It includes use in women with vasomotor symptoms and, in dependent claims, women with a uterus.
  • Claims 12 and 17 provide broader alternatives to the exact 196 mg/3 mg formulation.

Vulnerabilities

  • The independent claims are method claims rather than simple composition claims.
  • Food administration is required.
  • The claims require a particular indication and human patient population.
  • PK ranges may be vulnerable to enablement, written-description, indefiniteness, or reproducibility arguments depending on the specification and prosecution history.
  • “About” ranges and terms such as “uniformly dispersed” may require claim construction.
  • Claims 1 and 9 differ materially in “consisting of” versus “comprising” language.
  • Prior-art combinations involving oral micronized progesterone, estradiol, lipid vehicles, and self-emulsifying delivery systems may be relevant to obviousness.

The patent is more difficult to design around than a claim limited only to exact excipient quantities, but it does not automatically block every oral estradiol/progesterone capsule.

How does Bijuva compare with other menopausal hormone-therapy products?

Product Active ingredients Dosage form Progesterone present? Main distinction
Bijuva Estradiol 1 mg + progesterone 100 mg Oral softgel Yes Single-capsule continuous-combined therapy
Prempro Conjugated estrogens + medroxyprogesterone acetate Oral tablet Yes Different estrogen and progestin
Duavee Conjugated estrogens + bazedoxifene Oral tablet No Estrogen plus selective estrogen receptor modulator
Estrace plus Prometrium Estradiol plus micronized progesterone Separate products Yes Separate administration and products
Transdermal estradiol plus oral progesterone Estradiol patch/gel plus progesterone capsule Combination of dosage forms Yes Nonoral estrogen delivery

Competitors using a different estrogen, progestogen, route, or separate-product regimen generally present lower direct infringement risk under US 11,103,513. A competing oral softgel containing the same hormone doses and lipid delivery approach presents the highest risk.

What geographic coverage does the patent provide?

US 11,103,513 provides protection only in the United States. It does not directly control:

  • Canada
  • Europe
  • Japan
  • Australia
  • China
  • Latin America
  • Other national markets

Foreign family members must be assessed separately. The existence of a U.S. patent does not establish corresponding foreign rights, identical claim scope, or the same expiration date. National-phase prosecution, oppositions, annuities, terminal disclaimers, and local patent-term rules may produce materially different outcomes.

What manufacturing and IP barriers matter most?

The main technical barriers are:

  • Maintaining high estradiol solubilization.
  • Uniformly dispersing micronized progesterone.
  • Controlling progesterone particle-size distribution.
  • Achieving reproducible capsule fill weight.
  • Maintaining physical stability of the lipid suspension.
  • Reproducing fed-state absorption.
  • Demonstrating bioequivalence under FDA requirements.
  • Avoiding the claimed PK windows while remaining bioequivalent.
  • Controlling surfactant and medium-chain-oil ratios.
  • Establishing a defensible noninfringement position for an ANDA certification.

The manufacturing process itself may create additional trade-secret or process-patent exposure even where the final product is designed to avoid the claims of US 11,103,513.

Key Takeaways

  • US 11,103,513 protects methods using a Bijuva-type oral softgel containing 1 mg estradiol and 100 mg progesterone.
  • The claims require administration with food and treatment of menopausal vasomotor symptoms.
  • The patent combines formulation limitations with estradiol, estrone, and progesterone PK ranges.
  • Claims 1 and 9 focus on a named lipid system containing approximately 196 mg mono- and diglycerides and 3 mg PEG-32 glyceryl laurate-type surfactant.
  • Claims 12 and 17 provide broader functional and percentage-based formulation coverage.
  • Micronized progesterone particle size, solubilization percentage, and oil-to-surfactant ratios are important dependent-claim limitations.
  • Bijuva received FDA approval in 2018, and its three-year regulatory exclusivity has expired.
  • The product is subject to ANDA, not biosimilar, competition.
  • The expected family patent endpoint is approximately November 2, 2032, subject to the official USPTO and Orange Book records.
  • The highest generic-entry risk comes from an oral softgel that reproduces the formulation architecture and falls within the claimed PK ranges.

Frequently Asked Questions

Does US 11,103,513 cover all estradiol and progesterone products?

No. It targets specific oral capsule methods, formulation characteristics, administration with food, patient populations, and pharmacokinetic results.

Can a generic avoid the patent by changing the surfactant?

Potentially, but changing the surfactant alone may not avoid claims 12 or 17 if the alternative product still satisfies the broader functional limitations and PK requirements.

Is progesterone particle size relevant to infringement?

Yes. Claims 8 and 25 specifically address micronized progesterone with X50 and X90 particle-size thresholds.

Does the patent cover transdermal estradiol with oral progesterone?

Generally no, because the claims require a capsule containing both estradiol and progesterone administered orally with food.

Is a biosimilar pathway available for Bijuva?

No. Bijuva is a small-molecule drug. A competing product would generally use the ANDA pathway rather than the biosimilar pathway.

References

  1. U.S. Food and Drug Administration. (2018). Bijuva prescribing information, NDA 210366.
  2. United States Patent and Trademark Office. (2021). U.S. Patent No. 11,103,513.
  3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,103,513

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mayne Pharma BIJUVA estradiol; progesterone CAPSULE;ORAL 210132-001 Oct 28, 2018 RX Yes Yes 11,103,513 ⤷  Start Trial TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.